Evolving impact of long-term survival results on metastatic melanoma treatment.

ABSTRACT: Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number of patients. These results have prompted consideration of how best to define long-term benefit and cure. Now more than ever, oncologists should be aware of the long-term outcomes demonstrated with these newer agents and their relevance to treatment decision-making. As the first tumor type for which I-O agents were approved, melanoma has served as a model for other diseases. Accordingly, discussions regarding the value and impact of long-term survival data in patients with melanoma may be relevant in the future to other tumor types. Current findings indicate that, depending on the treat

SUBMITTER: Michielin O 

PROVIDER: S-EPMC7549477 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature